Several studies indicated that KPNA2 extensive expression in breast cancer patients was associated with a short overall patient survival and recurrence-free survival [20], [28], and may warrant consideration as a potential marker for chemoresistance in advanced breast cancer [24]. Here, KPNA2 is linked to breast carcinoma.